Chemomab Therapeutics Ltd DRC
$ 1.93
7.22%
07 Aug - close price
- Market Cap 14,142,400 USD
- Current Price $ 1.93
- High / Low $ 2.04 / 1.83
- Stock P/E N/A
- Book Value 1.49
- EPS -1.20
- Next Earning Report f
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.40 %
- ROE -0.71 %
- 52 Week High 4.12
- 52 Week Low 1.35
About
Chemomab Therapeutics Ltd. is dedicated to the research and development of biological drugs for the treatment of inflammatory and fibrotic diseases. The company is headquartered in Tel Aviv, Israel.
Analyst Target Price
$5.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-14 | 2026-03-19 | 2025-11-13 | 2025-08-14 | 2025-05-15 | 2025-03-03 | 2024-11-14 | 2024-08-21 | 2024-05-09 | 2024-03-07 | 2023-11-09 | 2023-08-14 |
| Reported EPS | -0.003 | -0.003 | -0.004 | -0.02 | -0.14 | -0.008 | -0.04 | 0.05 | -0.06 | -0.2654 | -0.07 | -0.14 |
| Estimated EPS | 0 | -0.01 | -0.04 | -0.04 | -0.2 | -0.01 | -0.04 | -0.04 | -0.06 | -0.02 | -0.08 | -0.16 |
| Surprise | -0.003 | 0.007 | 0.036 | 0.02 | 0.06 | 0.002 | 0 | 0.09 | 0 | -0.2454 | 0.01 | 0.02 |
| Surprise Percentage | None% | 70% | 90% | 50% | 30% | 20% | 0% | 225% | 0% | -1227% | 12.5% | 12.5% |
Next Quarterly Earnings
| Aug 2026 | |
|---|---|
| Reported Date | f |
| Fiscal Date Ending | o |
| Estimated EPS | r |
| Currency | m |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CMMB
2026-08-02 03:41:09
This article provides a detailed financial overview of Chemomab Therapeutics Ltd (CMMB), including its latest stock price, market capitalization, and P/E ratio. It presents a comprehensive look at the company's income statement, balance sheet, and cash flow statement, offering quarterly and annual data for various financial indicators like EPS, net profit, assets, liabilities, and equity. The report also includes an analyst rating of "STRONG BUY" and addresses frequently asked questions regarding key financial figures from the FY2025 earnings report.
2026-07-29 22:51:17
Chemomab Therapeutics Ltd (CMMB) closed at $1.540, up 7.69%, with a market capitalization of $44.35M. Analysts have given the company a "Strong Buy" rating with a target price of $15.00, suggesting a significant upside. The company is a clinical-stage biopharmaceutical firm focused on developing targeted therapies for fibrotic and inflammatory diseases.
2026-07-28 10:11:27
This article provides a technical analysis of Chemomab Therapeutics Ltd (CMMB) stock, focusing on various indicators and moving averages. It presents a summary of buy, sell, and neutral signals from indicators such as MACD, RSI, and TRIX, alongside moving averages like MA5 and MA10. The analysis concludes with a general signal of "Neutral" based on these technical factors.
2026-07-28 08:40:32
Chemomab Therapeutics Ltd (CMMB) is an Israel-based clinical-stage biopharmaceutical company focused on developing targeted therapies for fibrotic and inflammatory diseases. The company's therapeutic technology, BC-819, aims to destroy cancer cells without harming surrounding tissue. As of 2026Q1, 33 institutions hold shares of Chemomab Therapeutics Ltd, with institutional shareholding increasing compared to the previous quarter.
2026-07-27 18:10:37
This article provides details on the institutional confidence in Chemomab Therapeutics Ltd (CMMB), including its stock performance and key shareholder activities. It lists several institutional and individual shareholders, along with the shares they hold and their percentage change. The stock closed at $1.410 with a 3.68% increase, and its market cap is $40.61 million.
2026-07-26 22:10:33
This article provides an overview of Chemomab Therapeutics Ltd (CMMB) stock performance, showing a closing price of $1.360 with a -2.86% change. It highlights that critical revenue breakdown data by business segments and regions have not yet been disclosed by the company. The page serves as a placeholder for financial analysis, awaiting more detailed corporate disclosures.
